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Data-driven treatment selection for seamless
phase II/III trials incorporating
early-outcome data
Cornelia Ursula Kunz,a* Tim Friede,b,c Nick Parsons,a Susan Todd,d and
Nigel Stallarda
Seamless phase II/III clinical trials are conducted in two stages with treatment selection at the first stage. In the first stage,
patients are randomized to a control or one of k > 1 experimental treatments. At the end of this stage, interim data are
analysed, and a decision is made concerning which experimental treatment should continue to the second stage. If the
primary endpoint is observable only after some period of follow-up, at the interim analysis data may be available on some
early outcome on a larger number of patients than those for whom the primary endpoint is available. These early endpoint
data can thus be used for treatment selection. For two previously proposed approaches, the power has been shown to be
greater for one or other method depending on the true treatment effects and correlations. We propose a new approach
that builds on the previously proposed approaches and uses data available at the interim analysis to estimate these
parameters and then, on the basis of these estimates, chooses the treatment selection method with the highest probability
of correctly selecting the most effective treatment. This method is shown to perform well compared with the two previously
described methods for a wide range of true parameter values. In most cases, the performance of the new method is
either similar to or, in some cases, better than either of the two previously proposed methods. © 2014 The Authors.
Pharmaceutical Statistics published by JohnWiley & Sons Ltd.
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1. INTRODUCTION
Drug development is very expensive and risky with many com-
pounds failing in late development phases. Adaptive designs
have been recognized as a way to improve efficiency of drug
development by industry and regulators alike [1–3]. Of particular
interest are designs combining aspects of the clinical develop-
ment process into one single study that would have traditionally
been assessed in separate trials and phases, for instance, adaptive
seamless phase II/III designs [4–7]. Seamless phase II/III clinical tri-
als are conducted in two stages. In the first stage, patients are
randomized to control or some number k > 1 experimental
treatments. At the end of this stage, interim data are analysed,
and a decision is made concerningwhich experimental treatment
should continue, along with the control, to the second stage. If
the primary endpoint is observable only after some period of
follow-up, at the interim analysis, data may be available on some
early outcome on a larger number of patients than those for
whom the primary endpoint is available. These early endpoint
data can thus be used for guiding the choice of treatments to
continue. It has been demonstrated, for a range of settings, that
adaptive trial designs are generally more efficient, and thereby
quicker due to improved resource management, than conven-
tional programmes with phase II studies for treatment selection
and phase III studies for confirmation of the efficacy of the
selected treatments [8].
Two different procedures for incorporating early endpoint data
in a treatment selection design have been proposed by Stallard
[9] and Friede et al. [10]; the focus in this paper is on treatment
selection, general principles and methods for hypothesis testing
in adaptive seamless designs are discussed in detail elsewhere
[5,8,10], as are alternativemethods in the settingwhere early end-
point data are available at interim analysis [11,12]. Friede et al.
propose a method of treatment selection using early endpoint
data only. In contrast, Stallard uses any available final (primary)
endpoint data in addition to early endpoint data for treatment
selection at interim. Although both approaches differ in the way
in which data from the two stages are combined, they have
both been shown to control the type I error rate. In this paper,
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we propose a new data-driven methodology to pick the opti-
mal approach to treatment selection, which uses data available
at an interim analysis to estimate treatment effects and cor-
relations between endpoints and then, on the basis of these
estimates, chooses the treatment selectionmethodwith the high-
est probability of selecting the most effective treatment. This
new data-driven method is compared with the more established
data-driven methods of Friede et al. and Stallard for a wide range
of true parameter values. We focus here on using interim data
available at an early point in a trial to select the method to
undertake treatment selection. If, however, this was not possi-
ble, and it was necessary to decide on the appropriate method
at the planning stage, then one would have little option but to
rely on for instance other (external) sources of information or
data (possibly from a pilot study) to augment ones beliefs about
the likely effect sizes and associations between early and final
endpoints. Section 2 describes a randomized trial assessing the
efficacy of a novel compound in patients with primary hyperten-
sion, which provides a motivating example of how early outcome
datamight be used for decision-making at an interim analysis of a
seamless phase II/III trial. Appropriate notation is established, and
treatment selection for the two previously proposed methods is
described in detail in Section 3. The new data-driven selection
rule is developed in Section 4. Section 5 provides a worked exam-
ple of how selection probabilities are calculated using data from
the motivating example. In Section 6, numerical evaluation of
the new data-driven selection rule is undertaken in a simulation
study, and the performance of the newmethod is compared with
the two previously proposed methods. The paper concludes with
a discussion in Section 7.
2. MOTIVATING EXAMPLE
Calhoun et al. [13] report a double-blind, placebo-controlled,
randomized trial assessing the efficacy and safety of a novel
compound in patients with primary hypertension. The primary
efficacy endpoint was the change in clinic diastolic blood pres-
sure (DBP; mmHg) from baseline to the end of the 8-week
double-blind treatment period. A total of n=524 patients were
randomized to receive either one of four dose regimens of the
new anti-hypertensive, an active control (AC) or placebo for
8weeks. The standard deviation (SD) of the differences frombase-
line was assumed to be 10 mmHg in the sample size calculation.
Additional readouts of the primary endpoints were available at
weeks 1, 2 and 4. The primary comparisons were with placebo
(and not with the AC) using a multiple-contrast test [14] to con-
trol the familywise type I error rate at 0.025 one-sided. Figure 1
gives the differences in diastolic blood pressure (DBP) between
the dose regimens and AC with placebo over the time course of
the 8 weeks of double-blind treatment. The differences of dose
regimens 3 (DR3) and the AC to placebo at the end of the 8-week
treatment period were found to be statistically significant. These
two treatments also showed the biggest reductions in DBP at
weeks 2 and 4 in comparison to placebo. Here, we investigate the
possibility that a single interim analysis be undertaken at some
point before the trial endpoint had been observed on all patients,
but where, dependent on timing, a single early endpoint were
available on a group of patients, and additionally some primary
efficacy endpoint data were also available from a sub-group of
these patients at interim. We would expect both that differences
in DBP at different time points for the same patient would be cor-
related and that treatment effects on the earlier outcomes might
Figure 1. Differences in diastolic blood pressure (DBP) between active treatments
(i.e. dose regimens (DR) 1-4 and active control (AC)) and placebo over the time course
of the 8 weeks of double-blind treatment.
indicate the ordering of treatment effects for the final outcome.
This suggests that we might be able to use the early time point
data in the treatment selection at an interim analysis. The patients
were recruited into the trial over a period of about seven months.
Since the trial included a two-week washout and a two-week
single-blind run-in period, at an interim analysis half way through
recruitment, say after 4 months, only those patients recruited
during the first month would have had completed their 8-week
double-blind treatment period whereas the other patients could
have only contributed 1-, 2- or 4-week measurements to the
interim analysis. In what follows, wewill explore selection rules for
adaptive treatment selection at interim incorporating incomplete
patient follow-up data.
3. PHASE II/III CLINICAL TRIALSWITH EARLY
OUTCOME DATA
3.1. A flexible hypothesis testingmethod for phase II/III
clinical trials with early outcome data
Following, e.g. Stallard [9], we envisage a two-stage clinical
trial, in which in the first stage, patients are randomized to the
control treatment T0 or to one of k experimental treatments,
Ti , i D 1, : : : , k, with one of these experimental treatments, TI,
selected to continue, along with the control treatment, T0, to the
second stage.
We suppose that, at the end of the first stage, data are available
on the primary, final outcome for n1 patients in each treatment
group, but that in addition, early outcome data are available for
some larger number of patients, N1 per group. At the end of
the second stage, final outcome data will be available for all n2
patients receiving treatments TI and T0.
Denote by Xi,j and Yi,j respectively the early and final outcome
data from patient j in group i, i D 0, : : : , k, j D 1, : : : , n2. The
two endpoints for each patient are assumed to follow a bivariate
Pharmaceut. Statist. 2014, 13 238–246 © 2014 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.
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normal distribution with

Xij
Yij

 N

bi
Bi

,

20 w0
w0 
2

. (1)
Given the mean values, individual patients are assumed to be
independent so that cov

Xi,j , Xi0 j0
 D 0, cov Yi,j , Yi0 j0 D 0 and
cov

Xi,j , Yi0 j0
 D 0 for i ¤ i0 or j ¤ j0.
The parameters of interest are the treatment effects on the final
outcome for each treatment relative to the control, Bi  B0 ,
which will be denoted by i , i D 1, : : : , k, with H0i denoting the
null hypotheses i D 0, whichwill be tested against the one-sided
alternative hypotheses H1i : i > 0. The familywise type I error
rate may be controlled in the strong sense by application of the
closed testing procedure [15] and combination test [16,17]. Inter-
section hypotheses HS D TiS H0i , where S  f1, : : : , kg, are
tested using data from each of the two stages and combined
using a combination test. Individual elementary hypotheses H0i
are rejected at level ˛ if and only if all intersection hypothe-
ses with index sets that include i are rejected at individual local
test level ˛ [8]. Stagewise p-values, pS,1 and pS,2, are combined
using the weighted inverse normal method, with (pre-specified)
weights (w1 and w2) proportional to the planned sample size at
each stage, with HS rejected at level ˛ if C .pS,1, pS,2/  ˛ where
C .pS,1, pS,2/ D 1ˆ

w1ˆ1 .1  pS,1/ C w2ˆ1 .1  pS,2/

[18].
For  assumed known, a test of H0i may be based on standard-
ized test statistics using final endpoint data from stages one and
two given by
Zi,1 D
PN1
jD1

Yi,j  Y0,j

p
2N12
and
Zi,2 D
Pn2
jDN1C1

Yi,j  Y0,j

p
2 .n2  N1/ 2
.
Note that, in order to ensure independence between test statis-
tics from the two stages, Zi,1 uses data from all patients for
whom early endpoint data are available in stage one and Zi,2
uses data from only those patients recruited in the second stage.
From equation (1), Zi,j are normally distributed, with E .Zi,1/ D
i
q
N1=

22

, E .Zi,2/ D i
q
.n2  N1/ =

22

, var

Zi,j
 D
1, cov

Zi,j , Zi,j0
 D 0 for j ¤ j0 and cov Zi,j , Zi0 ,j D 1=2 for i ¤ i0.
The p-values for a test of each of the intersection hypotheses HS
at each stage may be obtained by a Dunnett test [19] that uses
the test statistic Zmax D maxi2S Zi,j . The second stage p-value for
a test of HS, pS,2, is set to pI, the p-value for selected treatment TI,
if I 2 S and to 1 if I … S, as in the conservative approach suggested
by Posch et al. [20].
This approach to hypothesis testing in the setting of treatment
selection with early endpoint data was proposed by Friede et al.
[10] who considered specifically the setting where early endpoint
data onlywere available for decisionmaking (treatment selection)
at stage one. Although they also propose a treatment selection
rule for use in this setting, the analysis approach controls the fam-
ilywise type I error rate in the strong sense for any treatment
selection method based on the data observed at the end of stage
one. An alternative treatment selection method for a setting in
which a combination of final and early endpoint data are available
from stage one was proposed by Stallard [9]. The treatment selec-
tion methods of Friede et al. and Stallard are described in detail in
the succeeding text.
3.2. Treatment selectionmethod of Friede et al.
Friede et al. [10] proposed amethod for selection of the treatment
TI that should continue to the second stage. In the setting they
envisage, early endpoint data only are available at the time when
the treatment selection is made, so that the selection does not
use any final endpoint data. Themethod can, however, be applied
when some final endpoint data are available, as discussed by Kunz
et al. [21].
Let
Zi D
PN1
jD1

Xi,j  X0,j

q
2N120
be the standardized test statistic based on the early endpoint
data from stage one. From equation (1), Zi are normally dis-
tributed with E .Zi,1/ D

bi  b0
q
N1=

220

, var .Zi,1/ D 1
and cov .Zi,1, Zi0 ,1/ D 1=2, i ¤ i0.
Treatment TI is then selected where I D argmax
˚
Zi

. The
probability that, e.g. treatment 1 is selected is therefore given by
Pr .select treatment 1 using Friede et al.method/ D
Pr

Z1 D max
˚
Zi
 D Pr Z2  Z1 < 0, : : : , Zk  Z1 < 0 .
This may be calculated using the joint distribution of Z2 
Z1 , : : : , Zk  Z1 given by
0
B@
Z2  Z1
...
Zk  Z1
1
CA  N
0
BBBBB@
0
BBB@
b2b1
0
q
N1
2
...
bk b1
0
q
N1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
.
Denoting by F.x,,†/, the cumulative distribution function of a
multivariate normal with mean  and variance-covariance matrix
† evaluated at x, we have
Pr .select treatment 1 using Friede et al.method/ D
F
0
BBBBB@
0,
0
BBB@
b2b1
0
q
N1
2
...
bk b1
0
q
N1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
,
(2)
where here 0 denotes the zero-vector with k  1 elements. Sim-
ilar joint distributions enable calculation of the probabilities that
other treatments are selected.
3.3. Treatment selectionmethod of Stallard
Stallard [9] proposed a method for selection of the treatment TI
that should continue to the second stage using a combination of
early and final endpoint data.
Let Si denote the standardized score statistic for i given all data
available at the end of stage one. For known  , 0 and w , Si is
given by
Si D
Pn1
jD1

Yi,j  Y0,j  w 0

Xi,j  X0,j  NXi C NX0

=n1

p
2=N1
where NXi D PN1jD1 Xi and N1 D n1N1= N1  2w .N1  n1/. With
 , 0 and w unknown, Si may be estimated using the double
2
4
0
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regression method of Engel and Walstra [22]; Galbraith and
Marschner [23] provide an analogous expression to the above
in the setting of a series of interim analyses at which the two
groups are compared, with the number of patients for whom
short-term and long-term data are available increasing through
the duration of the trial. Stallard and Kunz et al. show that
S1, : : : , Sk follow a multivariate normal distribution with E .Si/ D
i
q
N1 =

22

, var .Si/ D 1 and cov .Si , Si0/ D 1=2, i ¤ i0.
Stallard proposes selecting treatment TI where I D argmaxfSig.
The probability that, e.g. treatment 1 is selected is therefore
given by
Pr .select treatment 1 using Stallard method/ D
Pr .S1 D maxfSig/ D Pr .S2  S1 < 0, : : : , Sk  S1 < 0/ .
This may be calculated using the joint distribution of
S2  S1, : : : , Sk  S1 given by
0
B@
S2  S1
...
Sk  S1
1
CA  N
0
BBBBB@
0
BBB@
B2B1

q
N1
2
...
Bk B1

q
N1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
,
so that
Pr .select treatment 1 using Stallard method/ D
F
0
BBBBB@
0,
0
BBB@
B2B1

q
N1
2
...
Bk B1

q
N1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
.
(3)
As in the preceding text, similar joint distributions enable calcula-
tion of the probabilities that other treatments are selected.
3.4. Practical considerations
Successful application of the methods of Friede et al. [10] and
Stallard [9], described in Sections 3.2 and 3.3, depends in part
at least on the adequacy of the early endpoint as a surrogate
for the final endpoint. In a trial setting where a group of experi-
mental treatments (i.e. two or more) are compared with a control
the concept of group-level surrogacy corresponds to correlation
between the group means for the early (surrogate) and final end-
points, and analogously individual level surrogacy corresponds
to within-group correlation. For a fully validated surrogate end-
point, we require both individual and group-level surrogacy. For
the methods of both Friede et al. and Stallard, the use of an early
endpoint for decision making improves the power of the test.
However, the properties of the two methods are very different.
For the method of Stallard, the gain in power comes from the
within-group correlation between the early (surrogate) and final
outcomes (w); i.e. from the presence of individual-level surro-
gacy. Whereas for the method of Friede et al. unless there is a
large within-group correlation, the gain in power arises from the
correlation between treatment effects for the early and final out-
comes; i.e. from the presence of group-level surrogacy. The latter
property implies that in some settings, the Friede et al. method
could perform badly. For instance, consider a setting where the
bi ’s were widely spaced, but the Bi ’s were close together. The
method of Friede et al. will pick a treatment based on early out-
come data bi with high probability, but because of the close
spacing of the Bi ’s, it is likely that the selected treatment may
not perform equally well based on the final outcome. Clearly, the
Friede et al. methodology is only really sensible if the early end-
point data alone provide useful information for treatment selec-
tion; if it leads one to pick thewrong treatment(s), it is not sensible.
The Stallard method may do better in such settings, dependent
on the magnitude of w . So we would advise that before either
of these methods are used, some thought is given to the issues
discussed here, and the likely nature andmagnitude of all associa-
tions between early and final outcomes be considered during the
trial planning stage. Kunz et al. [21] provide a comparison of the
treatment selection rules proposed by Stallard and Friede et al.
They show that the properties of themethods depend on the true
unknown treatment effects and correlations between the end-
points, and that neither the Stallard method nor the Friede et al.
method is always preferable in terms of selection probability or
power. The new data-driven selection rule discussed in Section 4
describes how one might select which of the two methods to
use, but if one had strong beliefs or data to support one or other
methodology above the other at the planning stage of a trial, then
clearly the most sensible option would be to proceed with that
methodology.
4. A NEWDATA-DRIVEN SELECTION RULE
In this section, we introduce a new treatment selection method
based on the methods proposed by Friede et al. and Stallard.
The idea is that following observation of the data at the end of
stage one, both the methods of Friede et al. and Stallard will be
applied and compared. If both methods agree on which treat-
ment should proceed along with the control to the second stage,
the treatment indicated by both methods will be selected. If the
methods indicate that different treatments should proceed, the
stage one data will be used to assess which of the methods is
likely to be correct, as explained in more detail in the remainder
of this section, and the treatment indicated by this method will
be selected.
The aim is to provide a method that has high power, where
this is defined to be the probability of correctly selecting the
most effective treatment and rejecting the null hypothesis cor-
responding to this treatment having effect no greater than the
control treatment. This probability is bounded above by the prob-
ability that the most effective treatment is selected on the basis
of the data observed at stage one. In principle, it may be possi-
ble to compute the power analytically; however, it is very hard
compared with computation of the selection probabilities from
(2) and (3); our proposed method for choosing between the
treatment selection rules is based on the latter method.
Given observed stage one data, estimates of the effects,b and
B, variances, 0 and  , and the correlation, w , can be obtained.
These will be denoted by Ob, OB, O0, O and Ow , respectively.
On the basis of these estimates, we can calculate the estimated
probability of selection of each treatment for each of the two
methods given by (2) and (3), with the estimated probability of,
e.g. selection of treatment T1 given by
Pharmaceut. Statist. 2014, 13 238–246 © 2014 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.
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F
0
BBBBB@
0,
0
BBB@
Ob2 Ob1O0
q
N1
2
...
Obk  Ob1O0
q
N1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
, (4)
for the Friede et al. selection method and
F
0
BBBBB@
0,
0
BBB@
OB2 OB1O
q ON1
2
...
OBk OB1O
q ON1
2
1
CCCA ,
0
BBBBB@
1 12    12
1
2 1
. . .
...
...
. . .
. . . 1
2
1
2    12 1
1
CCCCCA
1
CCCCCA
(5)
for the Stallard selection method, where ON1 D n1N1=

N1
Ow2 .N1  n1/

.
These estimated selection probabilities give an indication
of the preference of each treatment based on each selection
method. For the Friede et al. and Stallard selection methods, the
treatments with the largest estimated selection probability is that
with the largest value of Zi and Si , respectively, and so will be
the treatments selected. When the two methods indicate selec-
tion of different treatments, we therefore propose to select the
method for which the estimated selection probability for the
selected treatment is largest. With the treatment selected in this
way, we propose to test the hypotheses H0i , i D 1, : : : , k using
the method as described in Section 3.1. As Friede et al. show that
this controls the familywise type I error rate in the strong sense
for any treatment selection method based on data from patients
enrolled in stage one of the trial, the familywise type I error rate is
strongly controlled.
5. EXAMPLE
The motivating example provides an informative setting in which
to demonstrate how selection probabilities are calculated for the
Stallard and Friede et al. methods. Let us consider the possibility
that an interim analysis were undertaken where early outcome
data, DBP at the 4-week assessment time point, were available
from N1 patients, and 8-week assessment data, the primary effi-
cacy endpoint, were available from n1 patients. For the selected
motivating example, we would expect there to be strong within
group correlations .w/between early (4-week) and final (8-week)
outcome data. Also, available data (Figure 1) suggest strong cor-
relations between treatment group effects, albeit the sample of
available treatment group means is small. Clearly, in this setting,
themethods of both Friede et al. and Stallard have potential appli-
cation, so it is of interest to understand under what conditions
one or other method performs the better. Depending on the tim-
ing of the interim analysis, we investigate two options; (i) where
4 week data were available from half of the target population
.N1 D 45/, and 8 week data were also available from a small pro-
portion .n1 D 10/ of these patients, and (ii) where the interim
analysis was undertaken at an earlier time point where N1 D 25
and n1 D 5. The AC treatment is always selected in addition to the
placebo. The parameters of interest, the effects for the four test
treatments, on the final outcome relative to the placeboBi B0
for i D 1, : : : , 4, are estimated from Figure 1 to be approximately
1.0, 0.6, 3.9 and 1.1 mmHg for treatments DR1, DR2, DR3 and DR4,
respectively. Similarly, the estimates of early outcome (4 week)
treatment effects relative to the placebo bi  b0 are estimated
from Figure 1 to be approximately 2.3, 3.4, 3.8 and 1.9 mmHg.
Given these estimates for Ob1 , : : : , Ob4 , OB1 : : : , OB4 , estimates for
early and final outcome standard deviations of O D O0 D 10 and
correlation parameter Ow D 0.9, treatment selection probabili-
ties for the Stallard and Friede et al. methods can be calculated
using expressions (4) and (5). These can be evaluated simply using
the pmvnorm function in the mvtnorm package [24] in R [25],
to give treatment selection probabilities for setting (i) of (0.102,
0.072, 0.716, 0.110) and (0.118, 0.337, 0.468, 0.076) for the Stal-
lard and Friede et al. methods respectively and for setting (ii)
treatment selection probabilities of (0.143, 0.113, 0.592, 0.152)
and (0.150, 0.324, 0.426, 0.110) for the two methods, all for treat-
ments DR1, DR2, DR3 and DR4 respectively. Both methods would
select treatment DR3 with highest probability, in both settings,
with setting (ii), where fewer patients were available, having lower
selection probabilities for the DR3 group. Treatment group DR2
illustrates where the methods can differ. For the Stallard method
the selection probability for this group is much smaller than for
the Friede et al. method, due to the relatively poor performance
of this treatment group at the 8-week assessment, from which
data are not used by the Friede et al. method for determining
selection probabilities. In general, the two methods may give dif-
ferent selection probabilities, the properties of these procedures
together with the data-drivenmethod are explored inmore detail
in a simulation study.
6. NUMERICAL EVALUATIONOF THE NEW
DATA-DRIVEN SELECTION RULE
6.1. Selection probability and power
In general, there are two different ways to define the selection
probability: (i) the probability to select any effective treatment
and (ii) the probability to select the most effective treatment.
Throughout this paper, we use the latter definition. In order to be
consistent with this definition, we also define the power as the
probability to reject the null hypothesis belonging to the most
effective treatment. Furthermore, we will, without loss of general-
ity, focus on T1 and report the probability of selecting T1 as well
as rejecting the corresponding null hypothesis, H01.
In this section, we report the results of a simulation study to
explore the properties of the new procedure. Results are shown
for a trial with three experimental groups, that is k D 3, compared
with a control group, T0, with n1 D 4, N1 D 32 and n2 D 64. For
treatment T1, we assume final endpoint effects, B1 , from 0.5 to
1 in steps of 0.1 and early endpoint effects, b1 , of -0.2, 0, and 0.2,
and we set B0 D b0 D 0, B2 D 12B1 , B3 D 14B1 , b2 D
1
2b1 and b3 D 14b1 to give early and final endpoint effects
of a half and a quarter of the size of the effect for T1. Note that
even forB1 < 0, the probability to select T1 is reported although,
in this case, this is the worst-performing treatment. We investi-
gate correlation w values of 0.9, 0.5, 0, 0.5 and 0.9. Results are
based on 10,000 simulations for each scenario considered. Sup-
plementarymaterial describes the results of additional simulation
studies, covering a wide range of alternative parameter settings.
Simulation results are shown in Figure 2. The panels on the
left-hand side of the figure show the probability of selecting treat-
ment T1 for the Stallard (black dashed line), the Friede et al. (black
dash-dotted line) and the data-driven method (black solid line).
The panels on the right-hand side show the probability of both
selecting treatment T1 and rejecting H01 at the ˛ D 0.025 level,24
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Figure 2. Selection (left) and rejection probabilities (right) for T1, as a function of final endpoint effectB1, using the Stallard [9], Friede et al. [10] and data-driven methods
for T1 early endpoint effect b1 D 0.2 and correlation between endpoints within each group w D f0.9,0.5, 0, 0.5, 0.9g; B2 D 12B1 , B3 D 14B1 , b2 D 0.1 and
b3 D 0.05.
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which is the power as defined in the preceding text, for the three
methods using the same line types.
For the Friede et al. method, the selection is based on early
endpoint data only. The selection probability for this method
thus does not depend on B1 or w . This is in contrast to the
selection probability for the Stallard method, which increases
with increasing B1 and, to a lesser extent, with the magnitude
of w .
For w positive, for B1 larger than about 0.3, the selection
probability for the data-driven method is mostly similar to that
for the Stallard method, i.e. the better of the two methods under
these scenarios. For B1 less than 0.3, the selection probability for
the new method is between that for the two previous methods.
For w less than zero, for B1 above about 0.3, the new method
leads to selection of treatment T1 with higher probability than
either the Stallard or Friede et al.methods.
Under the scenarios considered, the power is generally higher
for the Stallard selectionmethod than for the Friede et al.method.
The power for the new method is generally similar to that for the
Stallardmethod for larger w and greater than that for the Stallard
method for smaller or negative w .
In order to evaluate the performance of the data-driven
method, two boundaries can be defined against which the
data-driven method is then compared. The data-driven method
can only select a treatment group that was selected by at least
one of the Stallard and the Friede et al. method. An upper bound
for the selection probability for the newmethod is thus the prob-
ability that at least one of the Stallard and Friede et al. methods
selects treatment T1. This boundary is only meaningful if T1 is
the most effective treatment, that is if B1 > 0. An alterna-
tive to choosing between the treatments selected by the Stallard
and the Friede et al. methods using the data-driven rule intro-
duced in this paper is to randomly select between the treatments
recommended by the two methods when they disagree. The
selection probability for such an approach would be the aver-
age of that for the Stallard and Friede et al. methods. Although
not a lower bound for the selection probability, it is desirable
that the new method should perform at least as well as this
approach. The grey-shaded area in Figure 2 marks the range of
probabilities bounded by these two values. Ideally, the results for
the data-driven method should be between the boundaries and
as close as possible to the upper one. For the selection prob-
ability, we see that the data-driven method starts closer to the
lower boundary for smaller values of B1 but comes closer to the
upper boundary for higher values of B1 . A range of power values
defined similarly is shown on the plots on the right-hand side of
Figure 2. The power for the data-driven method is quite close to
the upper boundary for all scenarios considered.
To understand the results for the data-driven method in more
detail, the selection probability can be split up in three differ-
ent categories as illustrated by the grey lines on Figure 2: T1
was selected by the data-driven method because (1) the Stallard
method but not the Friede et al.method selected T1 (grey dashed
line), (2) the Friede et al. but not the Stallard method selected T1
(grey dash dotted line), (3) both the Friede et al. and the Stallard
method selected T1 (grey solid line). Note that the probabilities
for category (3) can be calculated using equation (6), given in
the succeeding text and that the results for the three categories
sum to the probabilities for the data-drivenmethod. As explained
above, it is more likely that both the Stallard and the Friede et al.
methods select T1 if the correlation is positive than if the corre-
lation is negative. For example, for B1 D 0, the probability that
all three methods select T1 is just about 10% for w D 0.9 but
about 26% for w D C0.9. On the other hand, the Stallard and
the data-driven method selected T1 in about 14% of the cases for
w D 0.9 but in only 4% of the cases for w D C0.9. Similarly,
in about 25% of the cases, the Friede et al. and the data-driven
method selected T1 if the correlation is negative, but in only 15%
of the cases if the correlation is positive.
6.2. Effect of w
It is interesting to note that although the selection probabili-
ties and power when using the Stallard or Friede et al. selection
method is the same for w of given magnitude, irrespective of
the sign, the properties of the new data-driven selection method
do depend on the sign of w . The selection probabilities for the
Friede et al.method and Stallardmethod are given by expressions
such as equations (4) and (5), respectively. The first of these does
not depend on w , and the second depends on w only through
N1 , which depends on 2w , but not on the sign of w . As the new
selection method is based on the treatments indicated by both
the Stallard method and the Friede et al. method, it is important
to note that the treatments selected by the two methods are not
independent, because they both depend on the early outcome
data Xi,j , i D 0, : : : , k, j D 1, : : : , n1. The probability that both
methods lead to selection of treatment T1 is obtained from the
joint distribution of Z2 Z1 , : : : , Zk Z1 , S2S1, : : : , SkS1, which
does depend on the sign of w , and is given by
0
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Joint distributions enabling calculation of the joint probability
of selection of other treatments by the Stallard and Friede et al.
methods are given by similar expressions.
The effect of the dependence on the sign of w is illustrated
in Table I, which gives the probabilities for each of the four cases
that T1 is selected by (i) the Stallard method but not the Friede
et al. method, (ii) the Friede et al. method but not the Stallard
method, (iii) both methods, (iv) neither of the methods, together
with the marginal distributions based on equations (2), (3) and
(6). The first two sub-tables give probabilities for w D ˙0.9. For
w D 0.9, T1 is selected by both methods with probability 0.21
compared with 0.39 for w D 0.9. On the other hand, both meth-
ods fail to select T1 with probability only 0.13 for w D 0.9 but
with probability 0.31 for w D 0.9. Conversely, for w D 0.9,
T1 is selected by at least one of the two methods with probabil-
ity 0.87 while for w D 0.9, T1 is selected by at least one of the24
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Table I. Probability of selecting T1 for the Stallard and Friede et al. methods for (a) B1 D 0.3, B2 D
0.15, B3 D 0.075, b1 D 0.2, b2 D 0.1 and b3 D 0.05, and (b) B1 D B2 D B3 D b1 D b2 D
b3 D 0 based on equations (2), (3) and (6).
(a) (b)
w D 0.9 w D C0.9 w D 1 w D C1
Stallard Stallard Stallard Stallard
No Yes Total No Yes Total No Yes Total No Yes Total
Friede No 0.13 0.33 0.46 0.31 0.15 0.46 0.33 0.33 0.67 0.67 0.00 0.67
Yes 0.33 0.21 0.54 0.15 0.39 0.54 0.33 0.00 0.33 0.00 0.33 0.33
Total 0.46 0.54 1.00 0.46 0.54 1.00 0.67 0.33 1.00 0.67 0.33 1.00
two methods with probability 0.69. As the data-driven method
can only select a treatment group that was selected by at least
one of the Stallard and the Friede et al. method, the differences
between the joint distributions for different signs of the correla-
tion lead to the different results for the data-driven method that
can be seen in Figure 2. An evenmore extreme example is given in
the last two subtables in Table I, when w D ˙1. In this case, when
w D 1, either the Stallard method or the Friede et al.method is
correct but never both of them, while for w D 1, the two meth-
ods always agree, so that the probability of at least one method
selecting treatment T1 changes from 0.33 to 0.67 depending on
the sign of w .
7. CONCLUSION
When a clinical trial with a primary endpoint that is observed only
after a relatively long follow-up period includes interim analyses,
it is desirable, if possible, to base these analyses at least in part
on more rapidly observable short-term endpoint data. In gen-
eral, any data available at the interim analysis could be used for
treatment selection, as long as the type I error rate is controlled.
Recently, Jenkins et al. [26] proposed a design for subgroup selec-
tion at interim using correlated survival outcomes. In this paper,
we have considered two-stage adaptive seamless phase II/III clin-
ical trials in which interim analysis data are used to decide which
of a number of experimental treatments should continue along
with the control treatment to the second stage. Two methods
have previously been proposed for the use of short-term end-
point data in this setting [9,10]. A comparison of the properties
of these methods [21] has indicated that neither method is uni-
formly more powerful than the other, but that each can be more
powerful depending on the (unknown) true values of the treat-
ment effects on long-term and short-term endpoints and the
correlation between the endpoints.
The method of analysis proposed by Friede et al. allows
considerable flexibility in terms of the choice of the rule used to
select the most promising treatment based on the interim data
observed. In particular, the selection rule itself may be chosen
in a data-dependent way based on data from patients recruited
in stage one of the trial whilst maintaining control of the fam-
ilywise type I error rate in the strong sense. This is the starting
point for the method proposed in this paper, in which, when
the Stallard and Friede et al. methods would lead to selection
of different treatments, the method that maximizes the selec-
tion probability based on parameter values estimated from the
observed data is used. The focus here has been on the devel-
opment of a novel methodological approach, so for reasons of
conciseness, we have not discussed some of the more practical
issues concerning implementation, for instance recruitment
patterns, whether recruitment should continue seamlessly and
what triggers the interim analysis. These are all key issues,
amongst many others, that would need to be considered when
deciding whether the methods described here might work in
any given setting; a fuller discussion of these issues is pro-
vided elsewhere [1,27]. Mainly, for reasons of clarity of exposition,
we have assumed fixed-effects models throughout this paper.
Random-effects models for the methods of Stallard and Friede et
al. have been discussed elsewhere [21], and also developed for
the newdata-driven approach of Section 4, but as the conclusions
and simulation results were not changed qualitatively, the simpler
fixed-effects approach only is presented here. We have restricted
discussion in this paper to the most simple setting of a two-stage
design where a single treatment is selected at an interim analy-
sis, using a single early endpoint. Future work will investigate how
this might be generalized to designs where more than one early
endpoint were available for treatment selection, more than one
treatment were selected at interim analysis and multiple (more
than two) stages were planned.
The comparison in the preceding text, together with additional
simulation results available as supplementary material, indicate
that the newdata-drivenmethod has power higher than the aver-
age of the two existing methods, which is higher than a strategy
that would pick one or other of the methods at random when
they disagree, for nearly all parameter values considered. The
only exceptions are when the treatment effect on the short-term
endpoint for treatment T1, b1 , is less than 0 and the treatment
effect for T1 on the long-term endpoint, B1 is close to 0, or when
b1  0 and w  1. In many cases, the new method is similar in
performance to the most powerful of the other two methods. In
some cases, the newmethod is better than either of the two exis-
ing methods, e.g. for large B1 , if w is close to 0 and b1 > 0, for
nearly all values of B1 > 0, if w is close to 1 and b1 > 0 and
for some B1 if w is close to 1 and b1 > 0.
The choice of whether or not to use the new data-driven
method depends on the level of confidence in predictions of
b1 , B1 , 0,  and w at the planning stage. If reliable estimates
are available, it is possible to work out which method will give
the best results based on equations (2), (3), and (6) and simula-
tion studies for the power as reported above. Depending on the
parameter estimates, as indicated above, the preferred method
could be one of the existing methods or the newmethod. If there
is uncertainty regarding parameter values, the new data-driven
method would be a good choice. In summary, the numerical
evaluations of the new data-driven methodology, presented in
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Section 6 and the supplementary material, show that the power
of the data-driven method was close to the upper boundary of all
the methods considered; i.e. it always performed relatively well.
Also, the new data-driven method was always similar in perfor-
mance to the more powerful of the two previously described
methods. That is, it was either marginally more or less powerful,
across all the scenarios tested, than the most powerful of either
the Stallard or the Friede et al. methods. More specifically, when
we assumed positive study findings for both early and final out-
comes, the new method generally performed better than either
the Stallard or the Friede et al. methods. Therefore, given that a
priori we would generally not know which of the two previously
described methods will perform the better, the new data-driven
method is a good choice, as it will perform nearly as well or often
better than either of the other methods.
The new data-driven method described here provides a
straightforward and appealing way of choosing between two
methods that have been suggested elsewhere for treatment
selection in the chosen setting, where up to now there was
no clear guidance. Our simulations have shown that this new
method generally performs well. The newmethod just represents
another way of using the data available at the interim analysis to
select a treatment, and we accept that this is somewhat arbitrary.
An interesting area for future work would be to attempt to make
this decision in an optimal way, perhaps using prior knowledge of
the expected magnitude of effects and associations between the
endpoints in a Bayesian setting.
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